Welcome to the Federated Health Intelligence Network
Collaborative research intelligence for academic and public health professionals
Submit Contribution
My Contributions
Submit Intelligence Signal
Share a clinical observation, regulatory update, or market signal with the FHIN network. All signals are reviewed before publication.
Profile Settings
Network Intelligence Feed
Live-
New Orphan Drug Designation: Neurodegenerative Program
FDA granted orphan drug status for investigational therapy targeting rare genetic neuropathy. Expedited review pathway activated.
-
Global Disease Burden Update: 2026 Epidemiological Shift
WHO releases revised burden of disease metrics indicating 12% increase in non-communicable disease prevalence across LMIC regions.
-
R01 Award: Oncology Research Collaboration Network
NIH funds multi-site collaborative studying immunotherapy resistance mechanisms in solid tumors. $8.2M commitment over 5 years.
-
Reimbursement Policy Shift: Real-World Evidence Framework
CMS updates coverage policy to recognize structured real-world data sources for post-market device evaluation and clinical outcomes reporting.
-
Accelerated Assessment Granted: Respiratory Innovation
EMA designates novel inhalation formulation for accelerated review, targeting unmet need in chronic respiratory disease management.
-
Committee Hearing: Drug Pricing and Transparency Mechanisms
U.S. House Committee on Energy and Commerce holds hearing on proposed pricing transparency legislation and international reference pricing models.